AI brief of an SEC Form 8-K · ASP Isotopes Inc. (ASPI)

ASP Isotopes says ENDRA filed Form S-4 for proposed Renergen merger

Neutral Impact 3 of 5 m&a Written later

ASP Isotopes disclosed that on October 2, 2026, ENDRA Life Sciences filed a Registration Statement on Form S-4 for the previously announced merger involving Noble Africa and Renergen. The merger remains subject to closing conditions, including approval by ENDRA stockholders, so shareholders should expect the transaction's outcome to depend on those steps.

Key points

Merger Agreement entered into on June 25, 2026, among ENDRA, ASP Isotopes, Noble Africa, Renergen and Kruger Merger Sub LLC
On October 2, 2026, ENDRA filed a Form S-4 Registration Statement containing a proxy statement and prospectus
Under the agreement, Merger Sub would merge with and into Noble Africa, which would survive as a wholly owned subsidiary of ENDRA
Closing is subject to conditions, including timely approval of the merger by ENDRA stockholders, if obtained at all

The filing

CompanyASP Isotopes Inc. (ASPI)

Form8-K, current report

Filed with the SECOct 2, 2026, 6:01 AM ET

Accession number0001477932-26-005971

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.